 |
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of...
Old and unwanted equipment and business assets are often worth far more than they appear particularly those containing valuable metals. Precious metals, led by gold and silver reaching record highs...
Daily Bulletin
Everyone wants to live life with independence and dignity. For people with disabilities, achieving this often requires the right support. This is where NDIS providers play an important role. These pro...
Daily Bulletin
In the modern world, where manufacturing has become highly interconnected, the weakest components of the supply chain can only make the chain as strong as it is. One defective component might cause ...
Daily Bulletin
